CIT Therapeutics Forms Strategic Partnership with IFLI, Securing Up to $2.5M to Advance Novel Cancer Therapies August 19, 2025
BriaCell Selected for MSK’s 2025 Therapeutics Accelerator Program for Bria-OTS+ for metastatic breast cancer, prostate cancer, and other cancers August 19, 2025
SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes August 12, 2025
Strand Therapeutics Raises $153M Series B Financing to Further Advance Programmable mRNA Therapeutic Pipeline August 12, 2025
NeOnc Technologies Awarded $2.5M in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia in Ph 2 trials August 12, 2025
ViroCell Biologics and AvenCell Therapeutics to accelerate development of novel allogeneic CAR-T therapies for blood cancers August 5, 2025
LIfT BioSciences granted €12M from Ireland’s Disruptive Technologies Innovation Fund to support the first-in-human clinical trial of LIfT’s IMAN therapy August 5, 2025
ARTBIO Announces $132 Million Series B Financing to Advance Pipeline of Alpha RLTs and Expand Manufacturing and Supply Chain Infrastructure August 5, 2025
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines including oncology July 29, 2025
Development of CY-101 for Cancers Driven by Dysfunction of Wnt/β-catenin Signalling to be Advanced Under International Nonproprietary Name of Getacatetide July 29, 2025
Dispatch Bio Launches to Deliver Universal Treatment Across Solid Tumors with Novel Immunotherapy Approach July 29, 2025
Sutro Biopharma Announces Research Collaboration with the FDA to Advance Regulatory Standards for ADCs July 29, 2025
Xenetic Biosciences Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform July 29, 2025
Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance July 29, 2025
Akari Therapeutics Continues Key Research on its Novel ADC Payload PH1 to Demonstrate its Ability to Target Cancers Fueled by Oncogenic Drivers July 29, 2025
Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib July 23, 2025
